Management of Intra-abdominal Infections due to Carbapenemase-Producing Organisms

Current Infectious Disease Reports

Volumn 16, Issue 10, 2014, Pages

  Di Carlo, Paola ^a   Vitale, Francesco ^a   Ó’Súilleabháin, Criostóir ^b   Casuccio, Alessandra ^a  

^a UNIVERSITY OF PALERMO   (Italy)

^b MERCY UNIVERSITY HOSPITAL   (Ireland)

Author keywords

Carbapenem resistant Enterobacteriaceae; Carbapenemase producing organisms; Intra abdominal infections; Management of intra abdominal infections

Indexed keywords

AMINOGLYCOSIDE; AMPHOTERICIN; ANTIBIOTIC AGENT; CARBAPENEM; CHLORAMPHENICOL; COLISTIN; DOXYCYCLINE; FOSFOMYCIN; FOSFOMYCIN CALCIUM; FOSFOMYCIN SODIUM; GENTAMICIN; MEROPENEM; MONOCLONAL ANTIBODY; PLAZOMICIN; POLYMYXIN; RIFAMPICIN; SOAP; TEMOCILLIN; TETRACYCLINE; TIGECYCLINE; TOBRAMYCIN; TROMETAMOL;

ABDOMINAL INFECTION; ABDOMINAL SURGERY; ANTIBIOTIC THERAPY; ANTIMICROBIAL THERAPY; CARBAPENEM RESISTANT ENTEROBACTERIACEAE; CARBAPENEM RESISTANT ENTEROBACTERIACEAE INFECTION; CARBAPENEMASE PRODUCING ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTION; HUMAN; INFECTION CONTROL; NONHUMAN; REVIEW; SEPTIC SHOCK;

EID: 84919433006     PISSN: 15233847     EISSN: 15343146     Source Type: Journal    
DOI: 10.1007/s11908-014-0428-7     Document Type: Review

References (63)

1. O'Suilleabhain CB, Kim S, Rodrick MR, Mannick JA, Lederer JA. Injury induces alterations in T-cell NFkappaB and AP-1 activation. Shock. 2001;15:432–7.
2. Pieracci FM, Barie PS. Management of severe sepsis of abdominal origin. Scand J Surg. 2007;96:184–96.
3. Niven D, Laupland K, Tabah A, Vesin A, Rello J, Koulenti D, et al. Diagnosis and management of temperature abnormality in ICUs: a EUROBACT investigators survey. Crit Care. 2013;17:R289.
4. Moore LJ, Moore FA. Epidemiology of sepsis in surgical patients. Surg Clin North Am. 2012;92:1425–43. The article provides definitions and guidelines for the screening and management of sepsis and septic shock.
5. Chen YH, Hsueh PR. Changing bacteriology of abdominal and surgical sepsis. Curr Opin Infect Dis. 2012;25:590–5. This review focuses on recent changes in epidemiological aspects of bacteria-induced intra-abdominal infections (IAIs).
6. Alexiou VG, Michalopoulos A, Makris GC, Peppas G, Samonis G, Falagas ME. Multi-drug-resistant gram-negative bacterial infection in surgical patients hospitalized in the ICU: a cohort study. Eur J Clin Microbiol Infect Dis. 2012;7–566. This study depicts certain, potentially modifiable, risk factors for postoperative infections in patients hospitalized in the ICU.
7. Zarkotou O, Pournaras S, Tselioti P, Dragoumanos V, Pitiriga V, Ranellou K, et al. Predictors of mortality in patients with bloodstream infections caused by KPC-producing Klebsiella pneumoniae and impact of appropriate antimicrobial treatment. Clin Microbiol Infect. 2011;17:1798–803.
8. Lee SS, Chen YS, Tsai HC, Wann SR, Lin HH, Huang CK, et al. Predictors of septic metastatic infection and mortality among patients with Klebsiella pneumoniae liver abscess. Clin Infect Dis. 2008;47:642–50.
9. Di Carlo P, Gulotta G, Casuccio A, Pantuso G, Raineri M, Farulla CA, et al. KPC - 3 Klebsiella pneumoniae ST258 clone infection in postoperative abdominal surgery patients in an intensive care setting: analysis of a case series of 30 patients. BMC Anesthesiol. 2013;3(1):13.
10. Solomkin JS, Mazuski J. Intra-abdominal sepsis: newer interventional and antimicrobial therapies. Infect Dis Clin North Am. 2009;23:593–608.
11. Gupta N, Limbago BM, Patel JB, Kallen AJ. Carbapenem-resistant Enterobacteriaceae: epidemiology and prevention. Clin Infect Dis. 2011;53:60–7. This review describes the current epidemiology of CRE in the United States and highlights important prevention strategy.
12. Woodford N, Turton JF, Livermore DM. Multiresistant Gram-negative bacteria: the role of high-risk clones in the dissemination of antibiotic resistance. FEMS Microbiol Rev. 2011;35:736–55.
13. Lolans K, Queenan AM, Bush K, Sahud A, Quinn JP. First nosocomial outbreak of Pseudomonas aeruginosa producing an integron-borne metallo-beta-lactamase (VIM-2) in the United States. Antimicrob Agents Chemother. 2005;49:3538–40.
14. Vatopoulos A. High rates of metallo-beta-lactamase-producing Klebsiella pneumoniae in Greece—a review of the current evidence. Euro Surveill. 2008;13(4).
15. Mazzariol A, Mammina C, Koncan R, Di Gaetano V, Di Carlo P, Cipolla D, et al. A novel VIM-type metallo-beta-lactamase (VIM-14) in a Pseudomonas aeruginosa clinical isolate from a neonatal intensive care unit. Clin Microbiol Infect. 2011;17:722–4.
16. Farr BM, Salgado CD, Karchmer TB, Sherertz RJ. Can antibiotic-resistant nosocomial infections be controlled? Lancet Infect Dis. 2001;1:38–45.
17. Bradford PA, Urban C, Mariano N, Projan SJ, Rahal JJ, Bush K. Imipenem resistance in Klebsiella pneumoniae is associated with the combination of ACT-1, a plasmid-mediated AmpC beta-lactamase, and the foss of an outer membrane protein. Antimicrob Agents Chemother. 1997;41:563–9.
18. Gazin M, Paasch F, Goossens H, Malhotra-Kumar S, MOSAR WP2 and SATURN WP1 Study Teams. Current trends in culture-based and molecular detection of extended-spectrum-β-lactamase-harboring and carbapenem-resistant Enterobacteriaceae. J Clin Microbiol. 2012;50:1140–6.
19. Harada S, Tateda K, Mitsui H, Hattori Y, Okubo M, Kimura S, et al. Familial spread of a virulent clone of Klebsiella pneumoniae causing primary liver abscess. J Clin Microbiol. 2011;49:2354–6.
20. Di Carlo P, Pantuso G, Cusimano A, D'Arpa F, Giammanco A, Gulotta G, et al. Two cases of monomicrobial intraabdominal abscesses due to KPC - 3 Klebsiella pneumoniae ST258 clone. BMC Gastroenterol. 2011;11:103.
21. Hirsch EB, Tam VH. Detection and treatment options for Klebsiella pneumoniae carbapenemases (KPCs): an emerging cause of multidrug-resistant infection. J Antimicrob Chemother. 2010;65:1119–25.
22. Brisse S, Fevre C, Passet V, Issenhuth-Jeanjean S, Tournebize R, Diancourt L, et al. Virulent clones of Klebsiella pneumoniae: identification and evolutionary scenario based on genomic and phenotypic characterization. PLoS One. 2009;4(3):e4982.
23. Kanhutu KN, Post JJ, Clezy KR, Foo HY. Community-acquired Klebsiella pneumoniae liver abscesses an “emerging disease” in Australia. Med J Aust. 2011;194:374–7.
24. Centers for Disease Control and Prevention (CDC). Guidance for control of infections with carbapenem-resistant or carbapenemase-producing Enterobacteriaceae in acute care facilities. MMWR Morb Mortal Wkly Rep. 2009;58(10):256–60.
25. Gastmeier P, Schwab F, Sohr D, Behnke M, Geffers C. Reproducibility of the surveillance effect to decrease nosocomial infection rates. Infect Control Hosp Epidemiol. 2009;30:993–9.
26. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; 21st informational supplement. M100-S21. Wayne: Clinical and Laboratory Standards Institute; 2011.
27. European Committee on Antimicrobial Susceptibility Testing: clinical breakpoint Table 3.1. EUCAST. 2013 http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Disk_test_documents/EUCAST_breakpoints_v1.3_pdf.pdf
28. Mochon AB, Garner OB, Hindler JA, Krogstad P, Ward KW, Lewinski MA, et al. New Delhi metallo-β-lactamase (NDM-1)-producing Klebsiella pneumoniae: case report and laboratory detection strategies. J Clin Microbiol. 2011;49:1667–70.
29. Limbago BM, Rasheed JK, Anderson KF, Zhu W, Kitchel B, Watz N, et al. IMP-producing carbapenem-resistant Klebsiella pneumoniae in the United States. J Clin Microbiol. 2011;49:4239–45.
30. Garau J. Other antimicrobials of interest in the era of extended-spectrum beta-lactamases: fosfomycin, nitrofurantoin and tigecycline. Clin Microbiol Infect. 2008;14 Suppl 1:198–202.
31. van Duin D, Kaye KS, Neuner EA, Bonomo RA. Carbapenem-resistant Enterobacteriaceae: a review of treatment and outcomes. Diagn Microbiol Infect Dis. 2013;75(2):115–20.
32. Peck KR, Kim MJ, Choi JY, Kim HS, Kang CI, Cho YK, et al. In vitro time-kill studies of antimicrobial agents against blood isolates of imipenem-resistant Acinetobacter baumannii, including colistin- or tigecycline-resistant isolates. J Med Microbiol. 2012;61(Pt 3):353–60.
33. Porres-Osante N, Azcona-Gutiérrez JM, Rojo-Bezares B, Undabeitia E, Torres C, Sáenz Y. Emergence of a multiresistant KPC-3 and VIM-1 carbapenemase-producing Escherichia coli strain in Spain. J Antimicrob Chemother. 2014
34. Hasan B, Perveen K, Olsen B, Zahra R. Emergence of carbapenem-resistant Acinetobacter baumannii in hospitals in Pakistan. J Med Microbiol. 2014;63(Pt 1):50–5.
35. Tängdén T, Hickman RA, Forsberg P, Lagerbäck P, Giske CG, Cars O. Evaluation of double- and triple-antibiotic combinations for VIM- and NDM-producing Klebsiella pneumoniae by in vitro time-kill experiments. Antimicrob Agents Chemother. 2014;58(3):1757–62.
36. Kallel H, Bahloul M, Hergafi L, Akrout M, Ketata W, Chelly H, et al. Colistin as a salvage therapy for nosocomial infections caused by multidrug-resistant bacteria in the ICU. Int J Antimicrob Agents. 2006;28:366–9.
37. Poulakou G, Kontopidou FV, Paramythiotou E, Kompoti M, Katsiari M, Mainas E, et al. Tigecycline in the treatment of infections from multi-drug resistant gram-negative pathogens. J Infect. 2009;58:273–84.
38. Sheng WH, Wang JT, Li SY, Lin YC, Cheng A, Chen YC, et al. Comparative in vitro antimicrobial susceptibilities and synergistic activities of antimicrobial combinations against carbapenem-resistant Acinetobacter species Acinetobacter baumannii versus Acinetobactergenospecies 3 and 13TU. Diagn Microbiol Infect Dis. 2011;70:380–6.
39. Daikos GL, Skiada A, Pavleas J, Vafiadi C, Salatas K, Tofas P, et al. Serum bactericidal activity of three different dosing regimens of colistin with implications for optimum clinical use. J Chemother. 2010;22(3):175–8.
40. Kontopidou F, Giamarellou H, Katerelos P, Maragos A, Kioumis I, Trikka-Graphakos E, et al. Infections caused by carbapenem-resistant Klebsiella pneumoniae among patients in intensive care units in Greece: a multi-centre study on clinical outcome and therapeutic options. Clin Microbiol Infect. 2014;20(2):O117-23.
41. Durante-Mangoni E, Signoriello G, Andini R, Mattei A, De Cristoforo M, Murino P, et al. Colistin and rifampicin compared with colistin alone for the treatment of serious infections due to extensively drug-resistant Acinetobacter baumannii: a multicenter, randomized clinical trial. Clin Infect Dis. 2013;57(3):349–58.
42. Gaibani P, Lombardo D, Lewis RE, Mercuri M, Bonora S, Landini MP, Ambretti S. In vitro activity and post-antibiotic effects of colistin in combination with other antimicrobials against colistin-resistant KPC-producing Klebsiella pneumoniae bloodstream isolates. J Antimicrob Chemother. 2014.
43. Akova M, Daikos GL, Tzouvelekis L, Carmeli Y. Interventional strategies and current clinical experience with carbapenemase-producing Gram-negative bacteria. Clin Microbiol Infect. 2012;18(5):439–48.
44. Corvec S, Furustrand Tafin U, Betrisey B, Borens O, Trampuz A. Activities of fosfomycin, tigecycline, colistin, and gentamicin against extended-spectrum-β-lactamase-producing Escherichia coli in a foreign-body infection model. Antimicrob Agents Chemother. 2013;57(3):1421–7.
45. Bodmann KF, Heizmann WR, von Eiff C, Petrik C, Löschmann PA, Eckmann C. Therapy of 1,025 severely ill patients with complicated infections in a German multicenter study: safety profile and efficacy of tigecycline in different treatment modalities. Chemotherapy. 2012;58(4):282–94.
46. Michalopoulos AS, Livaditis IG, Gougoutas V. The revival of fosfomycin. Int J Infect Dis. 2011;15(11):e732–9.
47. Falagas ME, Giannopoulou KP, Kokolakis GN, Rafailidis PI. Fosfomycin: use beyond urinary tract and gastrointestinal infections. Clin Infect Dis. 2008;46(7):1069–77.
48. Levy Hara G, Gould I, Endimiani A, Pardo PR, Daikos G, Hsueh PR, et al. Detection, treatment, and prevention of carbapenemase-producing Enterobacteriaceae: recommendations from an International Working Group. J Chemother. 2013;25(3):129–40.
49. Livermore DM, Warner M, Mushtaq S, Doumith M, Zhang J, Woodford N. What remains against carbapenem-resistant Enterobacteriaceae? Evaluation of chloramphenicol, ciprofloxacin, colistin, fosfomycin, minocycline, nitrofurantoin, temocillin and tigecycline. Int J Antimicrob Agents. 2011;37(5):415–9.
50. Merino M, Poza M, Roca I, Barba MJ, Sousa MD, Vila J, Bou G. Nosocomial outbreak of a multiresistant Acinetobacter baumannii expressing OXA-23 carbapenemase in Spain. Microb Drug Resist. 2013.
51. Cuzon G, Bonnin RA, Nordmann P. First identification of novel NDM carbapenemase, NDM-7, in Escherichia coli in France. PLoS One. 2013;8(4):e61322.
52. Tascini C, Sbrana F, Flammini S, Tagliaferri E, Arena F, Leonildi A, et al. Oral gentamicin gut decontamination for prevention of KPC-producing Klebsiella pneumoniae infections: relevance of concomitant systemic antibiotic therapy. Antimicrob Agents Chemother. 2014;58(4):1972–6.
53. Silvestri L, de la Cal MA, van Saene HK. Selective decontamination of the digestive tract: the mechanism of action is control of gut overgrowth. Intensive Care Med. 2012;38(11):1738–50.
54. Oudemans-van Straaten HM, Endeman H, Bosman RJ, Attema-de Jonge ME, van Ogtrop ML, Zandstra DF, et al. Presence of tobramycin in blood and urine during selective decontamination of the digestive tract in critically ill patients, a prospective cohort study. Crit Care. 2011;15(5):R240.
55. Riddle V, Mason J, Cebrik D, Kostrub C, Fong L, Hillan K J. The effect of plazomicin injection on the QT/QTc interval in healthy volunteers. ICAAC 2013, poster # A-017f. 1.
56. Walkty A, Adam H, Baxter M, Denisuik A, Lagacé-Wiens P, Karlowsky JA, Hoban DJ, Zhanel GG. In vitro activity of plazomicin against 5015 gram-negative and gram-positive clinical isolates obtained from patients in Canadian hospitals as part of the CANWARD study, 2011–2012. Antimicrob Agents Chemother. 2014.
57. Galani I, Souli M, Daikos GL, Chrysouli Z, Poulakou G, Psichogiou M, et al. Activity of plazomicin (ACHN-490) against MDR clinical isolates of Klebsiella pneumoniae, Escherichia coli, and Enterobacter spp. from Athens, Greece. J Chemother. 2012;24(4):191–4.
58. Tari LW, Li X, Trzoss M, Bensen DC, Chen Z, et al. Tricyclic GyrB/ParE (TriBE) inhibitors: a new class of broad-spectrum dual-targeting antibacterial agents. PLoS One. 2013;8(12):e84409.
59. Richter SG, Elli D, Kim HK, Hendrickx AP, Sorg JA, Schneewind O, et al. Small molecule inhibitor of lipoteichoic acid synthesis is an antibiotic for Gram-positive bacteria. Proc Natl Acad Sci U S A. 2013;110(9):3531–6.
60. Bugli F, Cacaci M, Martini C, Torelli R, Posteraro B, Sanguinetti M, et al. Human monoclonal antibody-based therapy in the treatment of invasive candidiasis. Clin Dev Immunol. 2013;2013:403121.
61. Rizzello L, Pompa PP. Nanosilver-based antibacterial drugs and devices: mechanisms, methodological drawbacks, and guidelines. Chem Soc Rev. 2013. This paper propose some general guidelines for the design of antibacterial nanosystems and devices based on silver/nanosilver.
62. Kruse EB, Aurbach U, Wisplinghoff H. Carbapenem-resistant Enterobacteriaceae: laboratory detection and infection control practices. Curr Infect Dis Rep. 2013. This review summarize the currently available laboratory methods and infection control options.
63. Ontario Agency for Health Protection and Promotion, Provincial Infectious Diseases Advisory Committee. Annex A—screening, testing and surveillance for antibiotic-resistant organisms (AROs). Annexed to: Toronto, ON: Queen’s Printer for Ontario; 2013.